Why doctors don't recommend long-term use of ensifentrine - Ohtuvayre

Although Ensifentrine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre has shown certain efficacy in the management of chronic obstructive pulmonary disease (COPD), doctors generally do not recommend long-term use alone, due to various factors including drug safety, efficacy maintenance, and COPD management strategies.

First of all, ensefentin is a new dualPDE inhibitor with limited long-term safety data. Continued use may bring risks of cardiovascular and systemic side effects, so caution is required in long-term management. Secondly, COPD is a complex chronic disease, and its treatment principles emphasize individualized, multi-drug combinations, such as bronchodilators, inhaled corticosteroids and anti-inflammatory drugs, to comprehensively control airway inflammation and improve lung function. Long-term use of a single drug may not adequately cover the multiple pathological mechanisms of the disease.

Third, drug tolerance and efficacy may decline over time in clinical practice, and long-term dependence on a single drug may lead to weakened efficacy or increased symptom fluctuations. At the same time, patients with COPD are often accompanied by multiple comorbidities, and long-term use of new drugs requires consideration of interactions with other drugs. Fourth, it has not yet been officially launched in China and the medical insurance coverage is unclear. The economic burden of long-term use is high, which may also affect the sustainability of treatment.

Therefore, doctors prefer to use exefantine as part of a short-term adjuvant or combination treatment program under professional monitoring so that the dose or combination of drugs can be adjusted at any time. In general, clinical experts emphasize that the application of exefantine should be based on safety, individualized management, and dynamic adjustment based on disease severity and patient quality of life to maximize efficacy and reduce potential risks.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html